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A B S T R A C T   
Autoimmune disorders are the third most common diseases in the United States, and affect the daily lives of 
millions of people. In this study, we analyzed patient samples, utilized a transgenic mouse model and human B 
cells to reveal Natural Killer Cell Transcript 4 (NK4) as a novel regulator that promotes the development of 
autoimmune disorders. NK4 was significantly elevated in samples from patients with Sjӧgren’s Syndrome (SS). SS 
patients show elevated NK4 levels. There is a strong and positive correlation between the increased levels of NK4 
and the duration of SS. Interestingly, transgenic expression of NK4 in a mouse model led to the development of 
autoantibodies and lymphocytic infiltration in salivary glands similar to those in SS patients. Those phenotypes 
were associated with increased B1a cells in the peritoneum, plasma cells in the spleen, and increased IgM, IgA, 
and IgG2a in serum of the NK4 transgenic mice. The autoimmune phenotypes became more severe in older mice. 
Moreover, after NK4 transfection, human naïve B cells were activated and memory B cells differentiation into IgG 
and IgA-plasmablasts, resulting in an increased production of autoantibodies.NK4 regulated the differentiation 
and activation of B cells through activating Rap1 activity. NK4 also promoted B cell migration in a paracrine 
fashion through an induction of CXCL13 in endothelial cells. Collectively, these findings identify NK4 as a 
promoter of the development of autoimmune disorders through its roles on B cells. Therefore, NK4 may be a 
novel therapeutic target for the treatment of autoimmune diseases.   
1. Introduction 
Autoimmune diseases arise from abnormal immune responses 
against substances and tissues normally present in the body. Depending 
on the type, an autoimmune disease can affect one or many different 
organs or tissues, damaging organ functions. According to the NIH 
Autoimmune Diseases Coordinating Committee Report 2002, autoim-
mune diseases are the third most common diseases in the United States 
after cancer and cardiovascular disease; they affect approximately 5%– 
8% of the population. Thus, identification of molecular mediators and 
investigating underlying functional mechanisms involved in the devel-
opment of autoimmunity are timely and necessary. Sjӧgren’s Syndrome 
(SS) is a chronic autoimmune disease affecting exocrine glands, pri-
marily salivary and lachrymal glands. Primary SS (pSS) is a common 
systemic autoimmune disorder that affects approximately 0.1–0.4% of 
the general population. The pathogenetic mechanisms of this autoim-
mune exocrinopathy have not been fully elucidated [1]. 
NK4 is a pro-inflammatory cytokine that activates p38 MAPK and 
NF-κB, thereby inducing pro-inflammatory cytokines. The gene was 
originally cloned as natural killer cell transcript[2] from activated 
human NK cells and T cells. It was renamed NK4 due to its ability to 
induce production of cytokines such as TNFα, IL-1, IL-6 and IL-8 [2,3]. 
Currently the human NK4 receptor has not been identified, and no ro-
dent orthologs of NK4 have been reported. NK4 is highly expressed in 
immune cells including monocytes and activated B cells [2,4], as well as 
endothelial cells [4–6]. NK4 has been shown to play a role in infection, 
including the defense against intracellular bacteria and viruses [7,8]. 
The levels of NK4 were significantly increased in RA patients [9,10]. 
Overexpression of NK4 in synovial fibroblasts resulted in a greater in-
duction of pro-inflammatory cytokines, and intra-articular introduction 
of NK4 in mice resulted in joint inflammation [9]. These reported 
findings suggest a potential role of NK4 in the development of autoim-
mune conditions. 
In analysis of patient samples, as well as utilizing a transgenic mouse 
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model and human B cells, we have discovered a causative role for NK4 in 
the promotion of development of autoimmune phenotypes. SS patients 
show elevated NK4 levels in serum and tissues. There was a strong and 
positive correlation between the serum levels of NK4 and the duration of 
SS. Consistent with the human data, transgenic expression of NK4 in 
mice led to spontaneous development of autoimmune phenotypes with 
elevated autoantibodies in the circulation, immunoglobulin deposition 
and lymphocyte infiltration into the salivary glands, similar to pSS 
patients. 
Mechanistically, NK4 promoted human B cell migration through the 
induction of CXCL13 in endothelial cells and monocytes, and efficiently 
stimulates naïve B cells activation and mediates memory B cells differ-
entiation into IgG and IgA-plasmablasts (PBs) through upgrading the 
activity of Ras-proximity-1 (Rap1). These results reveal a novel role for 
NK4 in promoting B cell maturation and activation, which leads to the 
production of autoantibodies and contributes to the development of 
autoimmune phenotypes. 
2. Materials and methods 
2.1. Human samples and mouse models 
The human specimens were obtained through NIH Institutional Re-
view Board approved protocols. Patients with primary Sjögren’s Syn-
drome (pSS) and healthy controls were recruited to the NIDCR Sjögren’s 
Syndrome Clinic. Minor salivary glands were obtained from the lower 
lips, and serum was isolated according to the clinic’s standard operating 
procedures. All primary Sjögren’s patients met the American-European 
Consensus Group criteria for diagnosis and there was no evidence of 
presence of other autoimmune diseases, such as Systemic Lupus Ery-
thematosus (SLE). The pSS population consisted of 22 females and 7 
males with a mean age of 54.3 years and a standard deviation of 15.7 
years (Suppl. Table 1). Twenty of the patients were Caucasians, seven 
were African American one was Asian and one was Hispanic. Healthy 
controls included 15 females with a mean age of 46.3 years and a 
standard deviation of 9.1 years. Eight of the females were Caucasians 
and seven were African American. All healthy controls were carefully 
examined for Sjögren’s syndrome and other autoimmune diseases. 
PECAM-NK4 transgenic mice in B6 background and wild type lit-
termates were maintained in a pathogen-free facility at the National 
Cancer Institute (Frederick, MD) in accordance with Animal Care and 
Use Committee regulations. Sex and age matched mice were used in all 
the studies. 
2.2. Primary cells and cell lines 
Human peripheral mononuclear cells (PBMCs) were isolated from 
pooled healthy donors (19–65 years age) at the NIH Blood Bank by 
centrifugation over a discontinuous Lymphoprep gradient. Human B 
cells were purified using CD19-mAb conjugated magnetic beads (Mil-
tenyi Biotec, Auburn, CA), respectively. More than 97% purity of the 
cells was attained for use in subsequent studies. Primary human um-
bilical vein endothelial cells (HUVECs) were from ATCC and Lonza, 
respectively. HUVECs were incubated in serum free EBM-2 (CC-3156, 
Lonza, Allendale, NJ) overnight, followed by the treatment of NK4 
transfection or shRAP1. 
2.3. Western blotting 
Human B cells isolated from Human PBMCs were transfected with 
Vector, NK4 or Rap1 shRNA, NK4 or Rap1 protein expression was 
analyzed in cell lysates by and probed with a goat anti-NK4 antibody 
(Ybdy biotech, South Korea) or anti-Rap1A + Rap1b antibody (Abcam, 
Cambridge, MA). NK4 plasmid was pCMV-EGFP-CMV-SV40 plasmid. 
The band intensities of Western Blot were analyzed using imageJ soft-
ware. The intensity ratios were quantified. 
2.4. Real-time PCR 
CXCL13 mRNA expression was determined by qPCR with the primer 












2.5. Autoantibody detection 
Anti-dsDNA IgG in serum was measured by ELISA following the 
manufacturers’ protocol (Alpha Diagnostic International, San Antonio, 
TX). Antinuclear antibody (ANA) was detected by an immunofluores-
cence assay on HEp-2 cells (BMD) with 1/100 diluted serum. ANA 
positive nuclei were counted in randomly selected fields under light 
microscopy. Mouse Ig Isotyping Array was used to determine immuno-
globulin sub-classes (IgG1, IgG2a, IgG2b, IgG3, IgA, IgD, IgE, and IgM) 
(Raybio® Rapid, Inc. Norcross, GA). Sixteen sera from WT and PECAM- 
NK4 mice were mixed with a Cy3 equivalent dye labeled antibody, and 
applied to the array. The slides were visualized and quantitated using a 
Genepix 4000A laser Scanner (Molecular Devices Inc. San Jose, CA). The 
SSA and SSB autoantibody ELISA is performed for the detection of IgG 
antibody to SSA or SSB in mouse serum following the manufacturers’ 
protocol (SE120117, SE120118, Sigma, St Louis, MO). 
2.6. Rap1 activity measurement 
Briefly, Goat Anti-Mouse IgG Magnetic Beads (S1431S, New England 
Biolabs, Ipswich, MA) were washed with lysis buffer and incubated with 
milk for 15 min. The anti-active Rap1a (26912, NewEast Biosciences, 
King of Prussia, PA) were then added and incubated for 30 min. The 
active Rap1 antibody suspension was washed and resuspended in dif-
ference lysis buffer separately. 100 μl active Rap1 antibody suspension 
above were added to the tubes containing 900 μL of human B cells lysate 
and incubated with rotation for 30 min at 4 ◦C. The samples with beads 
Table 1 
Comparison of splenic B cell subpopulations in 7-month-old PECAM-NK4 


















8.61 ± 1.01* 6.35 ± 1.13* 
*, P < 0.05. four mice in each group. 
a Splenic B cells were CD19+, marginal zone B cells CD19+/CD21hi/IgM+, 
germinal center B cells CD19+/B220+/GL-7+/IgDlo/-, and plasma cells CD19− / 
CD138+. 
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Fig. 1. NK4 levels are elevated in patients with pSS. (A) Sera from normal healthy subjects (n = 23) and pSS patients (n = 29) were analyzed for NK4 levels by ELISA 
and graphed (p = 0.02). The correlation among NK4 levels in patient sera and the sustain years of pSS patients (B), serum IgG from patients(C) and Minor Salivary 
Gland (MSG) focus score from those patients(D) were first diagnosed with oral symptoms were analyzed and plotted. (E) Immunohistochemistry on NK4 expression 
was performed on salivary glands from normal healthy donors and eight pSS patients (four patients in each group with two grades). Patient 1 represents samples 
collected from pSS patients with limited clinical inflammation, and patient 2 represents SS patients with moderate to severe inflammation. Representative images are 
shown. (F) Immunofluorescence double staining for NK4 and CD68 on salivary glands of pSS patients and health control donor, as described in Material and methods. 
DAPI staining is for cell nucleus. Representative images are shown. 
P. Qu et al.                                                                                                                                                                                                                                       
Journal of Autoimmunity 116 (2021) 102559
4
above were pelleted using magnet, and washed twice. The remaining 
buffer were removed carefully. The samples with beads above were 
resuspended in 1X Laemlii with reducing agent TCEP (tris(2-Carbox-
yethyl) phosphine), and were boiled to remove beads at 95 ◦C for 5min. 
The samples were harvested for Western blot. For the positive control 
use GTPyS containing lysis buffer, negative control use GDP containing 
lysis buffer, and experimental samples above need to be washed with 
buffer containing GTP and GDP. 
2.7. Histological analysis 
Mouse kidneys and parotid glands were harvested, fixed in 10% 
formalin, sectioned and stained with H&E for histological evaluation. 
For immunohistochemistry, the tissues were fixed in 4% para-
formaldehyde, sectioned and stained with anti-mouse CXCL13, B220, 
IgM, IgG antibodies, respectively. For Immuno-staining of human pSS 
patient’s salivary gland, anti-human CD68, B220 and NK4 antibodies 
were used. 
2.8. Flow cytometry 
Cells were stained with panels of antibodies including anti-mouse 
CD19-pacific Blue, CD138-APC, CD21-PEcy7, CD5-FITC, CD43-PE, 
IgD-APCcy7, CD38-PE-Cy7, GL-7-Percp (BioLegend, San Diego, CA), and 
IgM-APCcy7 (Miltenyi Biotec, Auburn, CA). For the human B cell phe-
notypes, the following antibodies were used: anti-CD19-pacific blue, 
anti-CD38-PECy7, anti- CD20-PE, anti-CD27-APCcy7 (BioLegend), and 
anti–human IgG-PE, anti– human IgA-APC (Miltenyi Biotec). BD Cyto-
fix/Cytoperm and BD Perm/Wash (BD) were used for IgA and IgG 
intracellular staining per manufacturers’ instructions. Data were 
analyzed on a BD Biosciences LSRII machine and Flowjo software 29. 
2.9. Protein array and ELISA 
Sera were collected from age and sex matched mice, and subjected to 
mouse Igs array and cytokine array (Proteome Profiler Array Mouse 
Cytokine, Raybio® Rapid, Inc. Norcross, GA). 
NK4 from the supernatant of human was detected by ELISA, as 
previously described as the protocol (reference in BioLegend). Briefly, 
anti-NK4 mouse monoclonal antibody (2 μg/ml, #513601; BioLegend, 
San Diego, CA) was coated onto a 96-well ELISA plate (BD Falcon, 
Franklin Lakes, NJ, USA). After blocking each well with 10% FBS in PBS 
supplemented with 0.05% Tween 20 (PBST) RT 1 h, human serum or a 
cultured medium supernatant was applied into each well, followed by 
Biotin anti-human NK4αβγδ Antibody (2 μg/ml, #513503; Biolegend) 
with enzyme SAV-HRP (BD bioscience, 1:250) for 2h RT. Color devel-
opment was measured by an ELISA reader. Recombinant IL-32 protein 
was used as standard protein (ab256059, Abcam, Cambridge, MA). 
The ELISA for IgG2a, IgG3, IgA and IgM were performed in 96-well 
plates coated with anti-murine IgG2a, IgG3, IgA and IgM (Sigma- 
Aldrich), respectively. For IgM ELISA, sera were diluted 1/2000 and for I 
IgG2a, IgG3 or IgA ELISA, sera were diluted 1/25,000 in PBS. Sera from 
NK4 -transgenic and WT mice were incubated in coated wells, washed, 
and then alkaline phosphatase-conjugated anti-murine IgG2a, IgG3 or 
anti-murine IgM was added, respectively. Plates were analyzed with a 
spectrophotometer after incubation with substrate. 
Sandwich ELISAs were used to measure human IgM, IgG and IgA. 
Capture and detection antibodies for Ig ELISAs were purchased from 
Southern Biotech. Human reference serum (Bethyl Laboratories, Inc. 
Montgomery, TX) was used to generate the standard curve for Ig ELISAs. 
Plates were read with a SpectraMax M2 (Molecular Devices Inc., 
Downingtown, PA) and analyzed with SoftMaxPro V5 software (Mo-
lecular Devices Inc. San Jose, CA). 
2.10. B cell migration 
Purified human CD19+ B cells were seeded in the upper chamber in 
3-μm Trans-well plates (Corning Costar, Cambridge, MA); HUVECs pre- 
transfected with Empty vector or NK4 were seeded in the bottom 
chamber. 
The Transwell was maintained at 37 ◦C for 24hrs with 5% CO2. The 
number of B cells that had migrated into the bottom chamber was 
determined by flow cytometry for CD19+ cells. For CXCL13 neutrali-
zation, increasing concentration of neutralizing CXCL13 antibody or an 
isotype control antibody (10 μg/ml) (R&D Systems) was used. Recom-
binant human CXCL13 (R&D Systems, Minneapolis, MN) at 500 ng/ml 
were applied as positive control in the bottom chamber. 
2.11. Statistical analysis 
Statistical analyses were performed using ANOVA by comparison of 
data between SS patient samples and healthy normal subjects. We per-
formed Cox proportional hazard regression to examine the relationship 
between NK4 serum levels and sustained times of Sjogren’s syndrome. 
Paired Student t-test was used for mouse studies and in vitro assays. The 
differences were considered statistically significant when P-value<0.05. 
3. Results 
NK4 levels are elevated in patients with pSS; and transgenic 
expression of NK4 in mice leads to the development of autoimmune 
phenotypes that resemble pSS. 
NK4 regulates the production of pro-inflammatory cytokines and its 
expression is elevated in chronic inflammatory and rheumatoid arthritis 
[10]. To test the hypothesis that NK4 may have a causative or triggering 
role in the development of autoimmune disease, we first examined the 
expression of NK4 in patients with pSS, a chronic autoimmune disease. 
Patients with primary Sjögren’s Syndrome (pSS) and healthy controls 
were recruited to the NIDCR Sjögren’s Syndrome Clinic. The patients 
were examined in detail when patients first started feeling the oral and 
ocular dryness. All pSS patients met the American-European Consensus 
Group criteria for diagnosis and there was no evidence of presence of 
other autoimmune diseases. All healthy controls were carefully exam-
ined for Sjögren’s syndrome and other autoimmune diseases (Suppl. 
Table 1). 
Upon analysis of NK4 levels in serum collected from normal healthy 
subjects and patients with pSS using ELISA, we found a significant in-
crease of NK4 in pSS patient samples compared to the age/sex matched 
normal subjects. The mean concentration of serum NK4 in pSS patients is 
864.97 ± 631.58 pg/ml and normal subjects 252.2 ± 235 pg/ml 
(Fig. 1A). To test whether the high level of NK4 on pSS patients is related 
with pSS disease development, we detected the relationship among NK4 
expression and pSS clinical characterization (such as sustain time of the 
diseases, IgG level and Minor Salivary Gland (MSG) focus score from 
those patients). There was a strong and positive correlation between the 
serum levels of NK4 and the duration of the disease R2 = 0.9137 
(Fig. 1B), and between the serum levels of NK4 and IgG protein level R2 
= 0.8904 (Fig. 1C). We did not find the relationship between the serum 
levels of NK4 and Minor Salivary Gland (MSG) focus score (Fig. 1D). We 
also acquired minor salivary gland tissues from multiple patients and 
healthy control subjects. The tissue sections were subjected to immu-
nohistochemical staining for NK4 expression. Notably, 75% of pSS pa-
tient biopsies (6 out of 8 patients) showed a positive reaction for NK4. In 
contrast, there was no detectable of NK4 deposition in tissues from 
normal healthy subjects. More NK4 positive cells were detected in pSS 
patients with moderate to severe inflammation compared to pSS patients 
with limited clinical inflammation (Fig. 1E). Double Immunofluores-
cence staining confirm NK4 expression on CD68+ myeloid cells (Fig. 1F). 
These clinical data demonstrated the strong correlation of NK4 expres-
sion with the patients with pSS. 
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Fig. 2. Transgenic expression of NK4 in one mouse model results in spontaneous development of autoimmune phenotypes. (A) Sera were collected from three and 
seven-months-old WT littermate controls and PECAM-NK4 mice. The levels of anti-dsDNA antibodies in sera were detected by ELISA and plotted (*p < 0.05, n = 23 
mice at 3 months of age; n = 15 mice at 7 months of age). (B) ANA was detected on HEp-2 cells using an indirect immunofluorescence assay. Representative ANA IgG 
staining of Hep-2 cells incubated with serum from 3 and 7-month-old WT and PECAM-NK4 Transgenic mice. The sample from PECAM-NK4 Transgenic mice shows a 
specked pattern. No or few positive cells were shown after incubated with samples from 3-or 7-month-old WT mice. (C) The number of ANA positive cells was 
counted in 10 randomly selected high-power fields under microscopy and graphed. *p < 0.05. (D) Anti-SSA autoantibody (Anti-Sjögren’s-syndrome-related antigen 
A, also called anti-Ro) was detected in sera from WT and PECAM-NK4 mice. (E) Salivary glands were harvested from 7 months old WT littermate control mice, 3 and 
7 months old PECAM-NK4 mice, sectioned and stained with HE and with an anti B220 antibody. White arrows point to infiltrating inflammatory cells. Bar = 50 μm. 
P. Qu et al.                                                                                                                                                                                                                                       
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To test if NK4 contributes to the development of autoimmune con-
ditions and investigate the underlying mechanism, we used PECAM-NK4 
transgenic mice, in which NK4 expression is driven by the PECAM-1 
promoter to direct the transgene expression in hematopoietic cells and 
endothelial cells[7]. Autoimmune diseases are developed when the 
healthy tissues and cells are targeted by the body’s own immune system 
and generate abnormal levels of autoantibodies. An analysis of serum 
from one and two-month-old PECAM-NK4 mice showed no detectable 
levels of autoantibody responses in circulation. However, starting from 
three-months of age, more than 50% of the female PECAM-NK4 mice (12 
out of 22) about 20% of male mice (5 out of 23) developed significant 
amounts of circulating autoantibodies against dsDNA. These levels 
further increased at seven-months of age in the PECAM-NK4 transgenic 
mice. In contrast, no autoantibody activity was detected in serum from 
WT littermate controls at either age group (Fig. 2A). 
The presence of anti-dsDNA antibody prompted us to further char-
acterize serum for the presence of antinuclear antibodies (ANAs). 
Consistently, we detected a very strong reaction of ANAs with serum 
from three-month old PECAM-NK4 mice, which also showed a more 
speckled pattern. The ANA reaction intensity further increased when 
Fig. 3. NK4 promotes the production of immunoglobulins in a mouse model. (A–D) Sera were obtained from PECAM-NK4 mice and WT littermate controls at 3 and 7 
months of age. Mouse Ig Isotyping Array was performed. Data shown are the mean and SD (n = 6 mice per group per time point. *p < 0.05). (E) Immunohisto-
chemistry was used to detect IgG and IgM deposition in salivary glands harvested from PECAM-NK4 mice and WT littermate controls at 3 and 7 months of age (n = 6 
mice per group per time point). Representative images are shown. Bar = 50 μm. (F) The percentage of B1a subgroup (CD19+ CD5+) in the peritoneal of NK4 
transgenic mice and WT control littermates was determined by flow cytometry (n = 6 mice per group, *p < 0.05). Each experiment was done in triplicate and 
repeated three times (*p < 0.05). 
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testing the serum from seven-month old PECAM-NK4 mice. In contrast, 
there were no detectable ANAs with serum from age and gender- 
matched WT littermate controls. Quantification of ANA positive cells 
confirmed a significant reaction in three-month-old PECAM-NK4 mice 
compared with WT controls. The reaction intensity of serum was 
increased in seven-month old PECAM-NK4 mice compared with those 
from the younger mice (Fig. 2B and C). The ANA staining patterns 
resemble the patterns in patients with pSS and SLE. The autoantibodies 
characteristics of pSS patients are Anti-SSA autoantibody (Anti- 
Sjögren’s-syndrome-related antigen A, also called anti-Ro) and Anti-SSB 
autoantibody (Anti-Sjögren’s-syndrome-related antigen B). Thus, we 
compared SSA and SSB expression in serum from between three-month- 
old PECAM-NK4 mice and age and gender-matched WT littermate 
controls. There is strong reaction of SSA and no reaction of SSB with 
seven-month-old PECAM-NK4 mice, compared with WT control 
(Fig. 2C, Suppl. Fig. 1). 
The development of autoantibodies could lead to tissue damage in 
target organs. Therefore, we harvested salivary glands and kidneys for 
histological examination. The majority of female PECAM-NK4 mice (12 
of 22 mice at three months of age, and 11 of 15 mice at seven months of 
age), but no littermate WT controls, developed multiple inflammatory 
cell infiltrations in salivary glands. There are not significantly difference 
between three- and seven-months old male mice. To determine what 
type of cells have infiltrated these tissues, we performed immune- 
histochemical staining on salivary gland from seven-month old 
PECAM-NK4 mice. We found the majority of the infiltrating inflamma-
tory cells are B220+ B cells. There was more inflammatory cell infil-
tration in seven-month old PECAM-NK4 mice than three-month-old 
PECAM-NK4 mice (Fig. 2E). The similar results were observed in kidney 
tissues from PECAM-NK4 mice and littermate WT controls (Suppl. 
Fig. 2). These results are indicative of tissue injury, and share similarities 
with the phenotypes observed in patients with pSS. The data from the 
analysis of human samples, along with our mouse model, collectively 
support a causative role for NK4 in the development of autoimmune 
disorders. 
3.1. NK4 promotes immunoglobulin production and B cell differentiation 
Next, we characterized immunoglobulin subtypes developed in the 
PECAM-NK4 mice by using an Immunoglobulin Isotyping Array (Suppl. 
Fig. 3A). The NK4 transgenic mice that developed autoantibodies by 
three-months of age showed a significant increase in Ig2a, IgG3, IgM and 
IgA levels compared with WT controls (Fig. 3A–D). By seven months, the 
PECAM-NK4 mice showed a further increase in IgM levels compared to 
those from three-month old PECAM-NK4 mice. The seven-month-old 
PECAM-NK4 mice also demonstrated a significant elevation of IgG2a, 
which was not increased in three-month old PECAM-NK4 mice 
(Fig. 3A–D). We did not detect any significant increase in other immu-
noglobulin subclasses between the two groups, such as IgG2b and IgG1 
(Suppl. Fig. 3B). Moreover, immune-histochemical analysis revealed a 
strong deposition of IgG and IgM in salivary glands harvested from 
PECAM-NK4 mice, but not from littermate controls at either three or 
seven-month of age (Fig. 3E). This is in complete agreement with B cell 
infiltration observed in salivary glands of the PEACM-NK4 mice 
(Fig. 2D). Similar deposition of IgG and IgM proteins was also detected 
in kidney tissues from the PECAM-NK4 mice and not in WT littermate 
Fig. 4. NK4 activates Naïve B cells in the presence of antigen.After naïve B cells were isolated by flow cytometry, those B cells were transfected with NK4 or empty 
vector. After 6 days, (A) NK4 overexpression were detected with Anti-NK4 through western blotting, (B) CD38 and CD20 expression on B cells from two groups were 
assessed by flow cytometry. (C) After naïve B cells were isolated by flow cytometry, those B cells were transfected with NK4 for 6 days in the presence of 50 nM CpG 
and 20 U/ml IL-2. Empty vector as control groups. CD69 and CD27 expression on B cells were measured on day 6th. (D) graph data are from three independent 
experiments with triplicate assay. *, P < 0.05, **p < 0.01. 
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controls (Suppl. Fig. 3C). Collectively, these data support the idea that 
abnormally high levels of circulating NK4 could activate B cells to over- 
produce IgG and IgA, thereby contributing to the development of 
autoimmune phenotypes. 
To further corroborate this hypothesis, we analyzed B cell develop-
ment and differentiation in the mouse bone marrow. There was no sig-
nificant difference in the total number of bone marrow cells between the 
PECAM-NK4 mice and age/sex matched WT littermate controls (Suppl. 
Fig. 4A). Nor did we detect any significant difference in the number of 
pre B cells (B220low IgM-) and immature B cells (B220low IgM+) be-
tween the two groups. However, there was a significant increase in the 
number of mature circulating B cells (B220high IgM+) in the PECAM- 
NK4 mice compared to WT mice (Suppl. Fig. 4B and 4C). This result 
implicates a specific role for NK4 in the regulation of B cell maturation 
and activation. 
Moreover, we examined subpopulations of B cells in the spleen and 
peritoneal cavities of mice at seven-months of age. A flow cytometry 
analysis of B1a cells (CD19+CD5+) detected a significant increase of 
these cells in the peritoneal cavity of the NK4 transgenic mice compared 
to WT littermate controls (Fig. 3F). Similarly, an analysis of spleen B 
cells using anti-CD19, CD21, CD38, CD138, GL-7, IgM and IgD anti-
bodies showed a significant increase of CD19+/CD21hi/IgM + marginal 
Fig. 5. NK4 induces CD19+ CD27+IgD + B cell responses by promoting IgG- and IgA-secreting B cell responses.CD19+ CD27+IgD + memory B cells were isolated by 
flow cytometry, and were transfected with NK4 for 6 days in the presence of 50 nM CpG and 20 U/ml IL-2. Empty vector as control groups. (A) CD38 and CD20 
expression on B cells from four groups were assessed after 6 days. (B) Experiments using 8 healthy human showed similar results. (C) Surface Ig staining on day 6. (D 
and E) Total Ig assayed by ELISA on day 6th. In B, D, E combined data (mean ± SD) from experiments using 8 healthy donors are presented. Data are from three 
independent experiments with triplicate assay. *, P < 0.05, **p < 0.01. 
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zone B cells, CD19+/B220+/GL-7+/IgDlo/-germinal center B cells and 
CD19− /CD138+ plasma cells in the NK4 mice compared to WT controls. 
The percentage of total CD19+ B cells in the spleen did not change be-
tween the two groups (Table 1). 
Collectively, these findings reveal a novel role for NK4 in promoting 
B cell maturation and activation, which leads to the production of au-
toantibodies and contributes to the development of autoimmune 
phenotypes. 
3.2. NK4 promotes naïve B cell activation 
To validate the findings from mouse models, we examined the effects 
of NK4 on human cells. Purified naive B cells (CD19+IgD + CD27− ) 
were transfected with empty vector or NK4. NK4 over-expression on 
Naïve B cells were detected through western blotting (Fig. 4A). The flow 
cytometry results demonstrated that NK4 cannot activate naïve B cells 
directly yet. (Fig. 4B). However, when purified naive B cells (CD19+IgD 
+ CD27− ) were transfected with empty vector or NK4 in the presence of 
IL-2 and CpG, NK4 enhanced CPG function on the activation of human 
naïve B cells (Fig. 4C and D). IL-2 can support human B cell proliferation 
and Ig productions [11]. CpG activates human naive B cells [12], 
resulting in enhanced proliferation and survival [13]. The results sug-
gest that NK4 activate naïve B cells in the present of CPG and IL-2. 
3.3. NK4 promotes memory B cell differentiation into IgG and IgA- 
plasmablasts 
We then tested whether NK4 could promote the differentiation of 
both CD19+IgD + CD27+ and CD19+IgD− CD27+ memory B cells into 
plasmablast. NK4 effectively induced IgD + CD27+ B cell differentiation 
into plasmablast (Fig. 5A and B), as measured by up-regulation of CD38 
and down-regulation of CD20 expression. NK4 also induce those B cells 
to produce switched isotypes, especially IgG and IgA (Fig. 5C). ELISA 
results confirmed that NK4 promote IgD + CD27+ B cell secrete IgG and 
IgA (Fig. 5D and E). Similar to IgD + CD27+ B cells, after IgD− CD27+
memory B cells were transfected with NK4, CD20− CD38+ plasmablast 
were induced for differentiation with secreted increased levels of IgG 
and IgA (Fig. 6A–C). Real-time PCR analysis of switch circle transcripts 
revealed that memory B cells transfected with NK4 had significantly 
increased levels of Iγ-Cμ and Iα-Cμ (Fig. 6D and E), which regulate IgM 
switch to IgG and IgA [13]. Collectively, NK4 displays a potent capa-
bility to enhance memory B cell differentiation into IgG- and 
IgA-plasmablasts. 
3.4. NK4 regulates B cell migration via induction of CXCL13 
To further investigate the mechanism that regulates B cell migration 
and infiltration into target organs, we performed a protein array and 
Fig. 6. NK4 induces CD19+ CD27+IgD- B cell responses by promoting IgG- and IgA-secreting B cell responses.CD19+ CD27+IgD-memory B cells were isolated by 
flow cytometry, and were transfected with NK4 for 6 days in the presence of 50 nM CpG and 20 U/ml IL-2. Empty vector as control groups. (A) CD38 and CD20 
expression on B cells from four groups were assessed after 6 days. Experiments using 8 healthy human showed similar results. (B and C) Total IgG and IgA assayed by 
ELISA on day 6th. mRNA was harvested, after memory B cells were transfected with empty vector or NK4 5–6 days. Real-time PCR was performed to measure the 
relative expression of switch circle transcript. Iγ-Cμ (D) or Iα-Cμ (E). Combined data (mean ± SD) from experiments using 8 healthy donors are presented separately. 
Data are from three independent experiments with triplicate assay. *, P < 0.05, **p < 0.01. 
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compared cytokine expression in serum from both PECAM-NK4 mice 
and age/sex matched WT littermate controls. Notably, there was a 
strong signal for CXCL13 in serum samples from the PECAM-NK4 mice 
compared to littermate controls (supple Figs. 5A and 2A). Since CXCL13 
is also called B cell chemo attractant, we reasoned that this chemokine 
might be responsible for B cell infiltration in salivary glands observed in 
the NK4 mice. Thus, we performed tissue staining and detected a sig-
nificant amount of CXCL13 reactivity in the inflammatory cells of sali-
vary gland tissues from the PECAM-NK4 mice compared to controls 
(Fig. 7B). Similar results were also obtained upon an analysis of kidney 
tissue samples from seven-months-old PECAM-NK4 mice (Suppl. 
Fig. 5B). In PECAM-NK4 mouse model, CXCL13 was expressed in in-
flammatory cells and vessels, suggesting that NK4 induces the produc-
tion of CXCL13 in host cells such as endothelial cells, and CXCL13 is 
responsible for the recruitment of B cells to target organs. In parallel 
studies, we found that CXCL13 was also expressed in vessels in salivary 
gland from pSS patients (Suppl. Fig. 5C). To test NK4 roles on endo-
thelial cells, we performed Transwell migration assays by seeding 
human naïve B cells in the upper chamber and HUVEC transfected with 
empty vector or NK4 in the bottom chamber. Flow cytometry was per-
formed to quantify the number of B cells that migrated into the bottom 
chamber. The results demonstrated that B cell migration was signifi-
cantly increased (Fig. 7C), due to more CXCL13 induction of NK4- 
treated HUVECs (Fig. 7D). Interestingly, addition of CXCL13 neutral-
izing antibody significantly blocked NK4/endothelial cell-induced B cell 
migration in a dose-dependent manner (Fig. 7E). These data suggest that 
NK4 promotes B cell migration in a paracrine fashion through an in-
duction of CXCL13 in surrounding cells such as endothelium in target 
organs. Tissue deposited CXCL13 provides the chemotactic signal for B 
cell recruitment. Notably, CXCL13 was abundantly expressed in 
endothelial-like structures throughout the inflamed salivary tissues from 
patients with Sjögren’s Syndrome. 
3.5. NK4 regulates B cell differentiation via the induction of Rap1 activity 
After Naïve B cells were transfected with Empty vector or NK4 for 
5–6 days, the increased activity of Rap1 were shown in NK4-transfected 
group (intensity ratio is 20.36, compared Vec group), but total Rap1 
protein level is slightly evaluated (intensity ratio is 1.57, compared Vec 
group, Fig. 8A), suggesting that NK4 upgrades the Rap1 activity. To 
confirm the concept further, we use Rap1shRNA to inhibit Rap1, after 
Human B cell were transfected with NK4 plasmid. The data demon-
strated that Rap1 shRNA block the activation of NK4-transfected naïve B 
cells (Fig. 8B–D). Thus, data indicated that NK4, as GEF protein, upre-
gulate activity of Rap1 to control B cells activation and differentiation. 
4. Discussion 
Autoimmune diseases are serious medical conditions affecting 
approximately 5%–8% of the US population. Therefore, identifying 
molecular mediators and studying the underlying mechanisms for 
autoimmunity are critically important. In present study, we used a 
combination approach of patient sample analysis and a genetic mouse 
model as well as human Naïve and memory B cells to demonstrate a 
novel role for NK4 in promoting the development of autoimmune 
disorders through upgrading the activity of Rap1. NK4 is significantly 
increased in the circulation and tissue deposition in patients with pSS, a 
chronic autoimmune disease affecting the body’s exocrine glands. The 
levels of circulating NK4 strongly and positively correlate with clinical 
characterization of pSS. In line with the patient data, transgenic 
expression of NK4 in a mouse model led to spontaneous development of 
autoimmune phenotypes that resembles to those observed in pSS pa-
tients, and the autoimmune properties worsen with age. Mechanistic 
studies show that NK4 regulates Naïve B cell activation, promote 
memory B cells differentiation into IgG and IgA-plasmablasts through 
up-regulating the activity of Rap1, and promotes B cell migration in a 
paracrine fashion through induction of CXCL13 in endothelial cells, 
thereby contributing to the development of autoimmune phenotypes 
(Fig. 8E). 
Although the pathogenesis of autoimmune diseases remains unclear, 
T cells, B cells, macrophages and endothelial cells are known to play 
crucial roles in the development of the diseases. NK4 is a pleiotropic 
factor that affects various types of cells including lymphocytes, myeloid 
cells and endothelial cells [3,4]. 
NK4, as GEF protein (unpublished data), regulates the activity of 
Rap1, is a member of Ras family of small G protein ubiquitously 
expressed in most tissues and mediates broad cellular activities. The 
Rap1 mediate cell integrins and other adhesion molecules to control cell- 
cell and cell-matrix adhesion [14]. Rap1GTP is inactivated by Rap1 
GTPase-activating protein, including Rap GAPs and SPA-1. The mice 
deficient for SPA-1 had shown the increased numbers of B1a cells pro-
ducing anti-dsDNA antibody and SLE through regulating the B cell re-
ceptor (BCR) repertoire [15]. Those results suggest that Rap1 signal may 
regulate the autoreactivity of BCR repertoire in BM immature B cells and 
tissue localization of potentially autoreactive mature B cells to lead to 
autoimmune disease [15,16]. Our results also confirmed it. PECAM-NK4 
Tg mice exhibited the increased number of peritoneal B1 cells and 
elevated serum IgM, IgG and IgA, and had increased surface IgG + B 
cells infiltration into tissues (Such as salivary gland and kidney), sug-
gesting that NK4 could promote Ig isotype switching in vivo, and induce 
tissues damage through regulating Rap1 signaling. In addition, our in 
vitro human data also demonstrated that NK4 can enhance Naïve B cell 
activation following treatment with TLR9 agonist CPG and IL-2, indi-
cating that, after human Naïve B cells were treated with NK4, Rap1 
activity in B cells were upregulated to modify BCR repertoire to upre-
gulate TLR9 expression in naïve B cell [15,17]. Even though TLR9 
agonist—CpG can activate naive CD27− B cells regardless of BCR 
cross-linking, their subsequent plasma-cell differentiation is a function 
of the in vitro culture conditions rather than an intrinsic biologic limi-
tation [12,18]. Therefore, NK4 lower response threshold for 
membrane-associated antigens to promote CPG-stimulated activation of 
B cells and cannot induce Naïve B cell differentiate into Ig switching 
plasmablast. 
Naïve human B cells produce both IgM and IgD, which are the first 
two heavy chain segments in the immunoglobulin locus. After activation 
by antigen, these B cells proliferate and became activated or memory B 
cells. When those B cells encounter specific signaling molecules via BCR 
or cytokine receptors, they undergo antibody class switching to produce 
IgG, IgA or IgE antibodies. Our results demonstrated that NK4 can 
promote human memory B cells differentiation into IgG-and IgA- 
Fig. 7. NK4 promotes B cell migration through CXCL13. (A) The protein array for immunofluorescence detecting chemokines/cytokines (spots relevant to this study 
are in a circle, showing chemokine CXCL13) of sera from 7-month-old PECAM-NK4 transgenic mice and littermate controls. CXCL13 protein levels are 6 times higher 
in serum from 7-month-old PECAM-NK4 transgenic mice than those from littermate controls. (B) Salivary gland tissues from three-month-old PECAM-NK4 mice and 
WT littermate controls were analyzed for CXCL13 expression by immunohistochemistry. Brown color marks CXCL13+ cells. Arrows point to blood vessels. 
Representative images are shown. (C) B cell migration was measured by a Transwell assay. Human CD19+ B cells and HUVECs were seeded into either the upper or 
bottom wells, respectively, with addition of empty vector or NK4 in the bottom chambers, and incubated for 24hrs. Migrated B cells in the bottom chamber were 
quantitated by flow cytometry for CD19+cells (*p < 0.05). (D) CXCL13 mRNA expression on HUVECs were measure using Real-time RT-PCR. (E) Identical conditions 
as in the Panel B were applied except with the addition of CXCL13 neutralizing antibody in the bottom chamber. Recombinant CXCL13 protein was used as a positive 
control, and isotype IgG was used as a negative control. Each experiment was performed in triplicate and repeated three times (*p < 0.05, **p < 0.01). (For 
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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plasmablast in the presence of CPG and IL-2. Human memory B cells can 
proliferate and differentiate into immunoglobulin (Ig)–secreting plas-
mablast in response to CpG [17]. However, Immunoglobulin class 
switching seldom occur. Toll-like receptor ligands (such as CPG) also 
sensitize BCR signaling that require actin severing by cofilin, which is 
regulated by activation of the Rap GTPase [19]. Therefore, memory B 
cells have lower activation thresholds and these cells can be rapidly 
activated in a non-antigen-specific manner by the combination of 
Toll-like receptor (TLR) agonists and a proliferation-inducing ligand 
(APRIL) (TNFSF13A) or BAFF (TNFSF13B) as well as by the combination 
of cytokines, such as IL-21 and BAFF [20]. Therefore, NK4 has potential 
capacity to induce Ig switching on memory B cells. The transgenic 
expression of NK4 also leads to elevated production and tissue deposi-
tion of IgM autoantibodies, B cell infiltration in salivary glands, and mild 
Fig. 8. NK4 regulates naïve B cells activation through upgrading Rap1 activity. (A) Naïve B cells were transfected with empty vector or NK4, NK4 and Rap1 protein 
were measured using western blotting. For detection of Rap1 activity, the protein was measured with activated Rap1 antibody, after IP, according to the Rap1 activity 
measuring protocol. The band intensities of WB were analyzed using imageJ software. The intensity ratios were calculated. (B) Rap1 protein was detected via western 
blotting, after naïve B cells were transfected with NK4 in the presence of empty shRNA or Rap1a shRNA for 6 days. Both representative WB results and their band 
intensity ratios were shown. (C) CD69 and CD27 expression on B cells above (B) were also measured. (D) graph data are from three independent experiments. *, P <
0.05, **p < 0.01. (E) One diagram of putative signaling pathway, by which NK4 regulates B cell differentiation and further induce autoimmune phenotypes such as 
tissues damage via upgrading Rap1 activity. 
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immune-complex mediated nephritis; all of which resemble the char-
acteristics of patients with pSS and SLE, which are known to involve 
excessive activation of B cells and the production of autoantibodies [21]. 
Notably, lymphocytic infiltration into salivary glands occurred months 
earlier than in the kidneys in PECAM-NK4 mice. This is also a feature 
common to pSS patients whose salivary glands are the first affected 
organs. Besides, the NK4 mice display increased numbers of B1a cells in 
their peritoneal cavities and splenic marginal zone B cells, as well as 
enhanced responses to vaccinations with antigens. These results provide 
cellular mechanisms for elevated serum levels of IgM in the NK4 
transgenic mice since the majority of IgM is derived from B1a cells and 
marginal zone B cells [22,23]. Constitutive activation of Rap1 can also 
antagonize Ras-dependent mitogen-activated protein kinase (MAPK) 
activation, likely via indirect effects of Rap1 on T cell ROS production. 
In this study, we found that NK4 had no direct effect on B cell 
migration, but it promoted B cell migration in a paracrine fashion 
through induction of CXCL13 in endothelial cells. CXCL13 is a B cell 
chemokine and its levels are increased in several autoimmune diseases 
[24–26]. In the current study, we observed CXCL13 deposition in the 
salivary gland and kidney from the autoimmune NK4 transgenic mice. 
Based on these data, it is conceivable to suggest that elevated NK4 
upregulates CXCL13 expression in inflamed endothelium and inflam-
matory cells in salivary glands, which provide a chemotactic signal for B 
cell recruitment to the target tissues. In addition, CXCL13-induced B-cell 
migration and adhesion are strongly dependent on activation of the 
Rap1 GTPase [27]. This interpretation is supported by the histological 
analysis of tissue sections from the NK4 mice that showed preferential 
accumulation of B cell infiltrates around blood vessels in target organs. 
Endothelial cells are known to produce CXCL13 [28], and this chemo-
kine is abundantly expressed on endothelial-like structures throughout 
the inflamed salivary tissues from patients with pSS [29,30]. 
In summary, the identification of NK4 as a critical component in the 
process of B cell maturation and activation resulting in the production of 
autoantibodies provides a new mechanism for the pathogenesis of 
autoimmune diseases. NK4 is elevated in patients with autoimmune 
disorders. NK4 mediates B cell migration, promotes B cell autoimmu-
nity, and enhances autoantibody responses to vaccinations. Thus, NK4 
might be both a target for treating autoimmune diseases and a 
biomarker for the diseases. 
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